Evidence map›Paper›PMID 39742367›Full record

ArticleThe breast journal2024

Supraclavicular Irradiation Induces Lymphedema in Breast Cancer Patients Treated with Axillary Lymph Node Dissection and Taxane-Containing Chemotherapy.

Nanae Horisawa, Akiyo Yoshimura, Isao Oze, Masataka Sawaki, Masaya Hattori, Haruru Kotani, Ayumi Kataoka, Yuri Ozaki, Kazuki Nozawa, Yuka Endo and 3 more

Abstract read
In one paragraph

Article in The breast journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nanae HorisawaDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0001-8457-5781
Akiyo YoshimuraDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-5274-9158
Isao OzeDivision of Cancer Epidemiology and Prevention Department of Preventive Medicine Aichi Cancer Center Research Institute, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-0762-1147
Masataka SawakiDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-2927-9258
Masaya HattoriDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-0935-9269
Haruru KotaniDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-0355-9294
Ayumi KataokaDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-4317-3804
Yuri OzakiDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0001-8382-7473
Kazuki NozawaDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-0277-8196
Yuka EndoDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-8415-3885
Daiki TakatsukaDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-2505-0640
Ayaka IsogaiDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-5545-5817
Hiroji IwataDepartment of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.ORCID 0000-0002-0242-4718

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Breast cancer-related lymphedema (LE) significantly impairs the patients' quality of life. Axillary lymph node dissection (ALND) is a strong risk factor for LE in breast cancer surgery. In addition, postoperative administration of docetaxel (DTX) has been reported to be a risk factor for LE in patients who undergo ALND. Herein, we performed the risk of objective LE after ALND. Methods: Patients who visited the medical follow-up clinic between 12 November 2018 and 11 January 2019 and at least one year postoperatively were eligible for this study. The risk factors for objective LE according to taxane-containing regimen, radiation therapy, and body mass index and the effects of a taxane-containing regimen followed by supraclavicular irradiation on LE were examined. Results: A total of 214 patients were included in this analysis, and objective LE was observed in 52 patients (24%). Univariate and multivariate analyses showed that only supraclavicular field irradiation was a statistically significant risk factor for objective LE. In addition, the sequential use of taxane-containing regimens and supraclavicular RT was shown to be a more likely risk factor for LE than ALND alone. We also compared each taxane regimen with supraclavicular RT and found that DTX was more likely to be a risk factor for LE in cases of sequential use of supraclavicular RT than with ALND alone. However, when comparing DTX with supraclavicular RT and PTX with supraclavicular RT directly, there was no statistically significant difference in the risk of objective LE between the two groups. Conclusion: The risk for LE was more likely to be higher with the sequential use of taxane-containing chemotherapy and supraclavicular field irradiation. Therefore, management of LE is important in these cases.

Indexed as

AxillaBreast NeoplasmsDocetaxelLymphedemaLymph Node ExcisionTaxoidsAdultAgedBridged-Ring CompoundsFemaleHumansMiddle AgedRetrospective StudiesRisk FactorsBridged-Ring CompoundsDocetaxeltaxaneTaxoids

Identifiers

PMID39742367
PMCPMC11306681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.